What is Semaglutide?
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.
Mechanism of Action
GLP-1 receptor (GLP1R) agonism: slows gastric emptying, suppresses glucagon, stimulates glucose-dependent insulin secretion, reduces appetite via hypothalamic GLP-1R signaling; 94% sequence homology to native GLP-1
Target: GLP-1 receptor (GLP1R)
Research Indications
Clinical trials demonstrate significant body weight reduction with sustained benefit
Improves glycemic control and A1C levels in type 2 diabetes
Associated with reduced cardiovascular events in high-risk patients
Addresses multiple components of metabolic syndrome simultaneously
Research Protocols
These are commonly discussed research protocols — not medical advice. Consult a healthcare provider before use.
| Goal | Dose | Frequency | Route |
|---|---|---|---|
| Starting Dose (Week 1–4) | 0.25 mg | Once weekly | Subcutaneous injection |
| Escalation (Week 5–8) | 0.5 mg | Once weekly | Subcutaneous injection |
| Standard Diabetes Dose | 1 mg | Once weekly | Subcutaneous injection |
| Weight Loss Maintenance | 2.4 mg | Once weekly | Subcutaneous injection |
Peptide & Drug Interactions
Always consult your healthcare provider before combining with other compounds. Use our Interaction Checker for reference.
How to Reconstitute & Inject
Use bacteriostatic (BAC) water only. Avoid saline — may cause precipitation. Refrigerate and use within 28 days.
- 1
Remove Semaglutide vial from refrigeration and allow to reach room temperature (15–20 minutes)
- 2
Clean vial top with alcohol swab and allow to air dry completely
- 3
Using a sterile syringe, draw the calculated volume of bacteriostatic water (BAC water)
- 4
Inject BAC water slowly down the side of the vial — do not aim directly at the powder
- 5
Gently swirl in circular motions — DO NOT shake vigorously as this degrades the peptide
- 6
Allow 2–3 minutes for full dissolution — solution should be clear and colorless
- 7
Draw calculated dose into an insulin syringe for subcutaneous injection
- 8
Inject into abdomen, thigh, or upper arm. Rotate injection sites to prevent lipodystrophy
- 9
Store reconstituted solution refrigerated (2–8°C) and use within 28 days
What to Expect
Week 1–2
Initial appetite suppression may begin. Mild GI effects (nausea, fullness) as your body adapts.
Week 2–4
Noticeable reduction in food cravings and portion sizes. Early weight changes begin.
Week 4–8
Significant appetite control and steady weight loss. Improved blood sugar if applicable.
Week 8–16
Substantial weight reduction and enhanced energy. Metabolic markers begin improving.
Week 16–24
Major weight loss milestone with cardiovascular benefits and improved lipid profiles.
Week 24+
Maximum clinical efficacy. Comprehensive metabolic improvements and sustained benefits.
Side Effects & Safety
- Nausea (most common, typically dose-dependent and transient)
- Diarrhea or constipation during dose escalation
- Vomiting, especially when starting or increasing dose
- Reduced appetite and early satiety
- Injection site reactions (redness, bruising)
- Fatigue, particularly in early weeks
- Rare: Pancreatitis — discontinue immediately with severe abdominal pain
- Rare: Thyroid C-cell effects (contraindicated with MEN2 or thyroid cancer history)
FDA Status & Regulatory Info
Semaglutide is a GLP-1 receptor agonist developed by Novo Nordisk and FDA-approved as Ozempic (type 2 diabetes, 2017), Wegovy (chronic weight management, 2021), and Rybelsus (oral daily, 2019). STEP 1 clinical trial demonstrated 14.9% average body weight reduction at 68 weeks with 2.4mg weekly. SELECT cardiovascular outcomes trial (2023) showed 20% reduction in major cardiovascular events.
Frequently Asked Questions
Research References
External links for education only. We do not control third-party content.
Community-reported data
The information below reflects self-reported experiences from PeptIQ app users. It is not clinical evidence and should not replace professional medical advice.
Community Intelligence
What 26 users report
Positive 4% · Neutral 96% · Negative 0%
Most reported benefits
Most reported side effects
Dose distribution
Median: 1000–2000 mcg · Most common: 2000+ mcg
Commonly stacked with
How repeat users are trending
Among repeat reporters, 78% said they felt similar to their last entry, 22% more positive, and 0% more negative.
Overall, repeat reporters leaned more positive than their previous entry.
Median gap between entries: 94 days · Based on 23 repeat reporters
Share Your Experience
Rate Semaglutide in the PeptIQ app and help the community make informed decisions.
Research purposes only
This page is for educational reference. It is not medical or legal advice. Consult the FDA and a licensed healthcare professional for current regulations and individualized guidance.